[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Watanabe N, Tsutsui J, Kakiuchi S, Jwa SC, Takahashi H, Kato N, Ozawa N, Sago H, Kitagawa M: Intra-Abdominal Bleeding during Pregnancy, Preterm Delivery, and Placental Polyp in a Long-Term Survivor of Neuroblastoma: A Case Report. Obstet Gynecol Int; 2009;2009:564567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-Abdominal Bleeding during Pregnancy, Preterm Delivery, and Placental Polyp in a Long-Term Survivor of Neuroblastoma: A Case Report.
  • Background. There are few reports of pregnancies in long-term survivors of pelvic neuroblastoma. Case.
  • A 30-year-old Japanese woman with a history of pelvic neuroblastoma in her childhood, which was treated with surgical resection, chemotherapy, and radiation.
  • She also had a placental polyp and developed massive postpartum bleeding.
  • Conclusion. Cancer treatment, especially radiation therapy, in childhood may cause adverse outcomes during pregnancy in long-term survivors of neuroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):10-6 [16458841.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):64-8 [15784827.001]
  • [Cites] Obstet Gynecol. 2001 Nov;98(5 Pt 2):929-31 [11704208.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Feb;16(1):24-8 [14768752.001]
  • (PMID = 20041132.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796213
  •  go-up   go-down


2. Feng C, Tang SQ, Wang JW, Liu Y, Yang G: [Curative effects of the protocol of CDV combined with CiE as pre-operative chemotherapy in high-risk childhood neuroblastoma]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Nov;11(11):885-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative effects of the protocol of CDV combined with CiE as pre-operative chemotherapy in high-risk childhood neuroblastoma].
  • OBJECTIVE: To evaluate the effects and the toxicity of the protocol of CDV combined with CiE as pre-operative chemotherapy in childhood stage IV neuroblastoma.
  • METHODS: The clinical data of 27 children aged from 1.2 to 8 years with neuroblastoma in stage IV was retrospectively studied.
  • The primary sites of the diseases were abdomen (n = 21), posterior mediastinum (n = 4) and pelvic cavity (n = 2).
  • Neuroblastoma therapeutic response evaluation criterion and common terminology criteria for adverse events of National Cancer Institute were used to evaluate effects and chemotherapy related toxicity.
  • RESULTS: All patients received the pre-operative chemotherapy.
  • After chemotherapy, 24 patients received operations.
  • The most common chemotherapy related toxicity was bone marrow suppression: grade IV suppression of neutrophils (n = 27), reduction in hemoglobin (III grade, n = 7; IV grade, n = 20) and reduction in platelet (III grade, n = 2; IV grade, n = 25).
  • I or II grade lesions of digestive, liver and kidney were found and could be recovered after therapy.
  • CONCLUSIONS: The protocol of CDV combined with CiE as pre-operative chemotherapy might be effective in children with stage IV neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20113653.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CVD protocol
  •  go-up   go-down


3. Pituch-Noworolska A, Zaremba M, Wieczorek A: Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol; 2009;60(4):168-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells.
  • The activity of multidrug resistance (MDR) proteins in tumour cells is associated with an increased resistance to therapy and in consequence with a decreased effectiveness of chemotherapy.
  • Neuroblastoma (NBL) and rhabdomyosarcoma (RMS) are common solid tumours of childhood.
  • The response to therapy is better in NBL, worse in RMS, but still unsatisfactory despite surgery and aggressive chemotherapy.
  • The high expression of an MDR protein profile in RMS suggests various mechanisms acting simultaneously, which might explain chemotherapy resistance and a low percentage of long-time survival in this tumour.
  • [MeSH-major] ATP Binding Cassette Transporter, Sub-Family B / metabolism. Drug Resistance, Neoplasm. Neuroblastoma / metabolism. Rhabdomyosarcoma / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / metabolism. Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / metabolism. Retrospective Studies. Vault Ribonucleoprotein Particles / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20072950.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


Advertisement
4. Ichino M, Tsuruta T, Ogawa A, Ichikawa T, Ishii K, Tomita Y: [A case of adult neuroblastoma arising in the retroperitoneal space]. Nihon Hinyokika Gakkai Zasshi; 2001 Sep;92(6):632-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult neuroblastoma arising in the retroperitoneal space].
  • Neuroblastoma, common in children, rarely develops in adults.
  • We recently treated a patient with adult neuroblastoma.
  • Chemotherapy with CDDP (cisplatinum), VP-16 (etoposide), BLM (bleomycin), ADM (adriamycin) was not effective.
  • Histopathological examination of a biopsy specimen revealed neuroblastoma.
  • Another chemotherapy with CPM (cyclophosphamide), VCR (vincristine), ADM, DTIC (dacarbazine), CDDP, VP-16 was effective in decreasing the tumor size.
  • Further high dose chemotherapy with CPM, ADM, CDDP, VP-16 combined with peripheral blood stem cell transplantation led to almost complete disappearance of the tumor and normalization of blood tumor markers (neuron specific enolase and immunosuppressive acidic protein).
  • Retroperitoneal lymph node dissection demonstrated well-differentiated neuroblastoma in the excised tissue.
  • Six months postoperatively, the tumor recurred in the pelvic cavity.
  • Although chemotherapy and radiotherapy were given, he died of the disease 12 months postoperatively.
  • [MeSH-major] Neuroblastoma. Retroperitoneal Neoplasms

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11593707.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Kubota M, Yagi M, Kanada S, Okuyama N, Kinoshita Y, Yamazaki S, Asami K, Ogawa A, Watanabe T: Long-term follow-up status of patients with neuroblastoma after undergoing either aggressive surgery or chemotherapy--a single institutional study. J Pediatr Surg; 2004 Sep;39(9):1328-32
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up status of patients with neuroblastoma after undergoing either aggressive surgery or chemotherapy--a single institutional study.
  • BACKGROUND/PURPOSE: Before adopting a national protocol of aggressive chemotherapy for patients with advanced neuroblastoma in 1985, the treatment strategies in use varied considerably among the institutions in Japan.
  • An aggressive surgical resection was the treatment of choice at the authors' institution before 1985.
  • To better understand treatment-related complications, the authors retrospectively investigated the long-term morbidity of patients who had reached adulthood.
  • METHODS: Sixteen patients with neuroblastoma currently 18 years of age or older were incorporated into the study.
  • All were non-mass screening cases, and 13 of the patients had undergone aggressive surgery, whereas the remaining 3 cases had received aggressive chemotherapy.
  • RESULTS: In the 13 patients who had undergone aggressive surgical treatment, a unilateral atrophy of the kidney was noted in 2 cases of adrenal and retroperitoneal neuroblastomas, respectively.
  • Dry ejaculation was noted in one case of a giant presacral neuroblastoma.
  • In the 3 patients who had undergone aggressive chemotherapy, severe hearing loss occurred in 2 cases.
  • CONCLUSIONS: Treatment-specific complications were found in both the aggressive surgery and chemotherapy groups.
  • These results should, therefore, be taken into account when developing future treatment protocols.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / surgery. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / surgery. Survivors
  • [MeSH-minor] Atrophy. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Doxorubicin / administration & dosage. Ejaculation. Follow-Up Studies. Hearing Loss, Sensorineural / chemically induced. Humans. Infant. Kidney / pathology. Leg Length Inequality / etiology. Lymph Node Excision. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Postoperative Complications / epidemiology. Radiation Injuries. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359385.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 18
  •  go-up   go-down


6. Loeser A, Gerharz EW, Riedmiller H: Recurrent pelvic neuroblastoma in an adult patient. Gynecol Oncol; 2007 Jul;106(1):257-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pelvic neuroblastoma in an adult patient.
  • BACKGROUND: Neuroblastoma is a common malignancy in children, but rarely occurs in adults.
  • CASE REPORT: We report the case of a 39-year-old woman who was treated for her fourth recurrence of a pelvic neuroblastoma.
  • CONCLUSIONS: Because of the rarity of these tumors during adolescence and adulthood, little information is available on the clinical course of patients with neuroblastoma in this age group.
  • Currently there is no standard treatment for adult patients with neuroblastoma.
  • Surgical resection and chemotherapy seem to be best of choice.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neuroblastoma / pathology. Pelvic Neoplasms / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466361.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Leclair MD, Hartmann O, Heloury Y, Fourcade L, Laprie A, Mechinaud F, Munzer C, Rubie H: Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology. J Clin Oncol; 2004 May 1;22(9):1689-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology.
  • PURPOSE: To assess the results and morbidity of treatment of children with localized pelvic neuroblastoma (NB).
  • PATIENTS AND METHODS: All consecutive cases of localized pelvic NB registered in the French multicenter prospective studies NBL90 and NBL94 between 1990 and 1999 were reviewed.
  • In unresectable tumors, primary chemotherapy (combinations of carboplatin-etoposide and vincristine-cyclophosphamide-doxorubicine) was administered before surgery.
  • At the end of treatment, 31 children were in complete remission (66%).
  • Survival of children treated with preoperative chemotherapy are similar to those treated by primary surgery (80% and 88% respectively).
  • CONCLUSION: Our data confirm the excellent survival of localized pelvic NBs.
  • Considering the efficacy of preoperative chemotherapy, patients with pelvic NB should be carefully screened for primary surgery.
  • [MeSH-major] Neoplasm Recurrence, Local. Neuroblastoma / drug therapy. Neuroblastoma / surgery. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Morbidity. Neoadjuvant Therapy. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117991.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Kushner BH, Laquaglia MP, Kramer K, Modak S, Cheung NK: Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatr Blood Cancer; 2008 Oct;51(4):552-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
  • An 8-year old child had a pelvic MYCN-nonamplified neuroblastoma (NB) with retroperitoneal nodal extension.
  • Multi-modality therapy achieved complete remission (CR).
  • Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4.9, 6.5, 7.5, 9.5, and 12.9 years from diagnosis.
  • When she returned 34 months later (16.8 years from diagnosis), she had massive disease in the left neck and upper trunk, without osteomedullary metastases.
  • Salvage therapy featured 11 cycles of temozolomide.
  • She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2814-9 [10706619.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):525-35 [11340607.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):536-40 [11340608.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):840-8 [14871959.001]
  • [Cites] Semin Oncol. 1992 Feb;19(1):47-84 [1736370.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3880-9 [9850034.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):315-8 [15735923.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):280-3 [16728498.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5259-64 [17114659.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5271-6 [17114661.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):132-9 [16317751.001]
  • [Cites] Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62 [17313156.001]
  • [CommentIn] Pediatr Blood Cancer. 2009 Apr;52(4):553 [19058212.001]
  • (PMID = 18570300.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA106450; United States / NCI NIH HHS / CA / CA106450; United States / FDA HHS / FD / FD-R-001041
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ NIHMS65895; NLM/ PMC4010138
  •  go-up   go-down


9. Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C, Perel Y, Valteau-Couanet D, Guitard J, Guys JM, Piolat C, Munzer C, Plantaz D, Groupe Neuroblastome de la Société Française d'Oncologie Pédiatrique: [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999]. Arch Pediatr; 2004 Jul;11(7):782-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999].
  • Neuroblastoma is the most frequent tumor observed in the newborn.
  • The aim of this study was to review clinical features, treatment and outcome of newborns diagnosed with a localized neuroblastoma.
  • RESULTS: The median age at diagnosis was 12 days (range 0-28) with antenatal detection in 14 patients (27%).
  • Tumor location was abdominal in 40 patients (adrenal in 20 of the 40), thoracic in eight, pelvic in three, and cervical in one.
  • One child died from hemorrhage after fine needle biopsy during diagnostic procedure.
  • Tumor was deemed as unresectable in 14 patients, and primary chemotherapy was given followed by surgical excision in 12.
  • One of them died a few days after the beginning of chemotherapy.
  • Indeed, chemotherapy based on weight and managed by expert teams should allow to perform surgical excision in safer conditions for unresectable tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / surgery
  • [MeSH-minor] Female. Humans. Infant, Newborn. Infant, Newborn, Diseases. Male. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234372.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Gao XN, Tang SQ, Lin J: [Clinical features and prognosis of advanced neuroblastoma in children]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug;9(4):351-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of advanced neuroblastoma in children].
  • OBJECTIVE: To investigate the clinical features, treatment modalities and the prognosis of advanced neuroblastoma in children.
  • METHODS: The medical records of 63 children with stage III or IV neuroblastoma from January 1996 to December 2005 were retrospectively reviewed.
  • Sixty patients were treated by tumor resection and (or) chemotherapy and (or) radiation.
  • RESULTS: Of the 63 patients with advanced neuroblastoma, the male/female ratio was 2.7:1 and the median age at diagnosis was 4 years old.
  • Primary tumor sites were adrenal (38%), retroperitoneal (35%), mediastinal (17%), pelvic (6%) and cervical (2%).
  • The sites of metastasis at diagnosis included local (41%) and (or) distant (37%) lymph nodes, bone marrow (60%), bone (46%) and liver (16%).
  • The median survival time of the 63 patients was 32.7 months.
  • Statistical analysis demonstrated that unfavorable survival prognostic factors were the following: age > 1 year at diagnosis (P < 0.05); serum neuro-specific enolase > 100 mg/L (P < 0.05); serum lactic dehydrogenase > 1500 U/L (P < 0.01); serum ferritin >150 mg/L (P < 0.05).
  • Intensive chemotherapy in combination with autologous peripheral blood stem cell transplantation could also result in a prolonged overall survival period (P < 0.01).
  • CONCLUSIONS: Neuroblastoma with advanced stages often presents with various clinical manifestations and has a poor prognosis.
  • It is beneficial to improve the prognosis of neuroblastoma through an early diagnosis and a comprehensive therapy including total resection of the primary tumor, autologous peripheral blood stem cell transplantation and intensive chemotherapy.
  • [MeSH-major] Neuroblastoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Prognosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706038.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Entz-Werle N, Marcellin L, Becmeur F, Eyer D, Babin-Boilletot A, Lutz P: The urinary bladder: An extremely rare location of pediatric neuroblastoma. J Pediatr Surg; 2003 Aug;38(8):E10-2
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The urinary bladder: An extremely rare location of pediatric neuroblastoma.
  • Pediatric malignant tumors in the urinary bladder are rare with a high prevalence of rhabdomyosarcomas.
  • Imaging studies disclosed a solid pelvic mass in the dome of the bladder confirmed by a cystoscopy.
  • Surprisingly, the biopsy done during this procedure confirmed a neuroblastoma with a favorable Shimada classification.
  • But, vessel compression and local infiltration led to delayed surgery, and neoadjuvant chemotherapy was initiated.
  • After chemotherapy, a complete surgical resection was accomplished.
  • Thus, urinary neuroblastoma seems to be a very rare pediatric tumor, but it should be considered in the differential diagnoses of urinary bladder tumor.
  • [MeSH-major] Neuroblastoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891516.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lobato R, Queizán A, Martínez L, Díaz M, Gámez M, Tovar JA: [Impact of complete resection on survival of patients with large neuroblastoma]. Cir Pediatr; 2000 Jan;13(1):14-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of complete resection on survival of patients with large neuroblastoma].
  • The aim of our study is to assess the role of complete resection after chemotherapy in stage 3 and 4 (INSS) neuroblastoma.
  • 47 were abdominal, 13 thoracic, 2 pelvic and 1 cervical.
  • CONCLUSIONS: Complete resection in stage 3 neuroblastoma after chemotherapy improves survival, and radical surgery seems justified even if neighboring structures have to be removed.
  • Radical surgery does not seem to be useful in stage 4 neuroblastoma.
  • [MeSH-major] Ganglioneuroma / mortality. Ganglioneuroma / surgery. Neuroblastoma / mortality. Neuroblastoma / surgery
  • [MeSH-minor] Child, Preschool. Humans. Infant. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12602016.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


13. Moon SB, Park KW, Jung SE, Youn WJ: Neuroblastoma: treatment outcome after incomplete resection of primary tumors. Pediatr Surg Int; 2009 Sep;25(9):789-93
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
  • PURPOSE: For International Neuroblastoma Staging System (INSS) stages III or IV neuroblastoma (intermediate or high risk), complete excision of the primary tumor is not always feasible.
  • Most current studies on the treatment outcome of these patients have reported on the complete excision status.
  • The aim of this study is to review the treatment outcome after the incomplete resection.
  • Incomplete resection was assessed by review of the operative notes and postoperative computerized tomography.
  • Age, gender, tumor location, INSS stage, N-myc gene copy number, pre- and postoperative therapy, and treatment outcome were reviewed.
  • The treatment outcome was evaluated according to the postoperative treatment protocol in the high-risk group.
  • RESULTS: Intermediate-risk patients were treated with conventional chemotherapy, isotretinoin (ITT) and interleukin-2 (IL-2).
  • Before the introduction of PBSCT, the high-risk patients were also treated with the conventional chemotherapy (N = 19).
  • For the high-risk patients (N = 32), 19 patients were treated with chemotherapy alone; 15 patients died of their disease while four patients currently have an NED status.
  • CONCLUSIONS: For intermediate risk, conventional chemotherapy appears to be acceptable treatment.
  • However, for high-risk patients, every effort should be made to control residual disease including the use of myeloablative chemotherapy, differentiating agents and immune-modulating agents.
  • [MeSH-major] Neuroblastoma / mortality. Neuroblastoma / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Dermatologic Agents / therapeutic use. Female. Follow-Up Studies. Genes, myc. Humans. Infant. Interleukin-2 / therapeutic use. Isotretinoin / therapeutic use. Male. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Neoplasm, Residual. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1256-64 [9552023.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1007-13 [19171716.001]
  • [Cites] Semin Surg Oncol. 1993 Nov-Dec;9(6):489-92 [8284567.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Neuroimmunol. 1999 May 3;96(2):201-6 [10337918.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1706-15 [9473237.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):953-65 [9508178.001]
  • [Cites] J Pediatr Surg. 2002 Nov;37(11):1574-8 [12407542.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):185-92 [12880980.001]
  • [Cites] J Pediatr Surg. 2004 Mar;39(3):412-7; discussion 412-7 [15017562.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2024-30 [9516847.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):242-7 [12692423.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2417-26 [8823319.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Hematother. 1997 Jun;6(3):235-42 [9234178.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):931-6 [15185228.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23 (2):169-72 [10197803.001]
  • (PMID = 19629500.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Interleukin-2; EH28UP18IF / Isotretinoin
  •  go-up   go-down


14. Paulino AC, Fowler BZ: Risk factors for scoliosis in children with neuroblastoma. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):865-9
MedlinePlus Health Information. consumer health - Scoliosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for scoliosis in children with neuroblastoma.
  • PURPOSE: To determine the risk factors for scoliosis in children treated for neuroblastoma.
  • METHODS AND MATERIALS: From 1957 to 1997, 58 children with neuroblastoma were treated at one institution and have survived a minimum of 5 years.
  • There were 35 boys and 23 girls with a median age of 6 months (range, 2 weeks to 15 years) at initial diagnosis.
  • Primary site was located in the adrenal gland in 25 (43.1%), abdominal/nonadrenal in 16 (27.6%), thoracic in 12 (20.7%), cervical in 3 (5.3%), and pelvic region in 2 (3.5%).
  • The International Neuroblastoma Staging System (INSS) stage was Stage 1 in 10 (17.2%), Stage 2A in 7 (12.1%), Stage 2B in 5 (8.6%), Stage 3 in 22 (37.9%), Stage 4 in 4 (6.9%), and Stage 4S in 10 (17.2%).
  • Thirty-three (56.9%) received chemotherapy whereas 5 (8.6%) had a laminectomy as part of the surgical procedure.
  • Twelve (21%) developed scoliosis at a median time of 51 months (range, 8-137 months).
  • Four had scoliosis ranging from 30 degrees to 66 degrees ; 3 of these patients required surgical intervention, whereas 1 had an underlying Duchenne muscular dystrophy which manifested itself 8 years after diagnosis of neuroblastoma.
  • Median time to scoliosis was 23 months (range, 8-54 months) in children who had a laminectomy.
  • Gender, age at diagnosis, INSS stage, primary site, and use of chemotherapy were not found to be significant.
  • CONCLUSIONS: Treatment-related factors, namely laminectomy and radiotherapy, were found to increase the risk of scoliosis in patients with neuroblastoma.
  • [MeSH-major] Neuroblastoma / radiotherapy. Scoliosis / etiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Laminectomy / adverse effects. Male. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage. Risk Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Scoliosis.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708267.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gatcombe HG, Marcus RB Jr, Katzenstein HM, Tighiouart M, Esiashvili N: Excellent local control from radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1549-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent local control from radiation therapy for high-risk neuroblastoma.
  • PURPOSE: Local recurrence has been demonstrated in previous studies to be one of the obstacles to cure in neuroblastoma.
  • Radiation therapy indications, optimal dose, and technique are still evolving.
  • Here we report our experience of high-risk neuroblastoma patients who received local radiation therapy as part of their cancer management.
  • METHODS AND MATERIALS: We conducted a retrospective study of 34 high-risk neuroblastoma patients who received radiation therapy to local sites of disease from March 2001 until February 2007 at our institution as part of their multimodality therapy.
  • Both of these patients had persistent gross disease after induction chemotherapy and surgery.
  • CONCLUSION: Patients with high-risk neuroblastoma in our series achieved excellent local control.
  • Doses of 21-24 Gy to the primary tumor site appear to be adequate for local control for patients in the setting of minimal residual disease after induction chemotherapy and surgery.
  • [MeSH-major] Neuroblastoma / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / surgery. Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Gene Amplification. Genes, myc / genetics. Humans. Infant. Male. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / mortality. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Risk. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / mortality. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211198.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR 3rd, Fallon RJ, Rescorla FJ: Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg; 2006 Feb;41(2):377-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in patients with stage IV neuroblastoma.
  • AIM OF STUDY: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse.
  • Age at diagnosis was 29.1 +/- 31.7 months in survivors.
  • Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1).
  • Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1.
  • Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation.
  • CONCLUSION: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy.
  • New methods of treatment are required to achieve better outcomes.
  • [MeSH-major] Neuroblastoma / pathology. Neuroblastoma / therapy. Survivors
  • [MeSH-minor] Child, Preschool. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481255.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Plantaz D, Michon J, Valteau-Couanet D, Coze C, Chastagner P, Bergeron C, Nelken B, Martelli H, Peyroulet MC, Carpentier AF, Armari-Alla C, Pagnier A, Rubie H: [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists]. Arch Pediatr; 2000 Jun;7(6):621-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists].
  • In children, it could be a paraneoplastic syndrome in association with neuroblastoma, usually with a high survival rate, but having a high frequency of neurologic and psychologic sequelae.
  • OBJECTIVES: The aim of this study was to describe oncologic outcome (prospectively) and neurologic outcome (retrospectively) in children with non-metastatic neuroblastoma, and to determine its best treatment.
  • PATIENTS AND METHODS: Data were collected on 21 children diagnosed with localized neuroblastoma and opsoclonus-myoclonus between 1990-1999 from the French Society of Pediatric Oncology institutions.
  • RESULTS: Median age at diagnosis was 18 months.
  • Location of the tumor was abdominal in 14 cases, thoracic in three cases, pelvic in three cases, and cervical in the last case.
  • Only four tumors were initially considered as unresectable tumors and received first-line chemotherapy.
  • Complete macroscopic resection was performed in 20 cases (four after primary chemotherapy).
  • Nine children received chemotherapy.
  • Treatment for opsoclonus-myoclonus varied widely.
  • Only one child received no medical treatment for opsoclonus-myoclonus, because of complete resolution of neurologic symptoms after exclusive surgery.
  • The following agents were used: corticosteroids in 18 cases, intravenously immune globulin in five cases, and antiepileptic drugs in seven cases.
  • Ten patients experienced relapses of opsoclonus-myoclonus symptoms, mainly related to the decrease of steroid therapy (5/10).
  • There is no correlation between neurologic outcome, and either age at diagnosis or duration of neurologic symptoms, or type of treatment of the tumor, particularly chemotherapy.
  • CONCLUSION: Persistent neurologic deficits are characteristic for children with neuroblastoma and opsoclonus-myoclonus.
  • Neurologic outcome seems unrelated to the treatment of neuroblastoma, which should exclusively be conducted according to oncological criteria.
  • The treatment of opsoclonus-myoclonus should be standardized, mainly based on high-dose hydrocortisone, with a very low decreasing dosage, associated to intravenously immune globulin in severe cases.
  • [MeSH-major] Neuroblastoma / complications. Paraneoplastic Syndromes, Nervous System / etiology
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Anticonvulsants / therapeutic use. Child. Female. Humans. Immunization, Passive. Male. Prognosis. Prospective Studies. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Dancing Eyes-Dancing Feet Syndrome.
  • Genetic Alliance. consumer health - Myoclonus.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10911528.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants
  •  go-up   go-down


18. Paulino AC, Mayr NA, Simon JH, Buatti JM: Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1025-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.
  • PURPOSE: To review patterns of failure in infants with neuroblastoma and determine late toxicity and efficacy of radiotherapy (RT) on locoregional control.
  • MATERIALS AND METHODS: From 1955 to 1998, 53 children (35 males and 18 females) <1 year old with neuroblastoma were seen at our institution.
  • All infants were retrospectively staged according to the International Neuroblastoma Staging System (INSS); 8 had Stage 1, 7 Stage 2A, 6 Stage 2B, 15 Stage 3, 6 Stage 4, and 11 Stage 4S.
  • Postoperative doses ranged from 15 to 25 Gy whereas preoperative doses ranged from 12 to 31 Gy using a median fraction size of 1.5 Gy.
  • Chemotherapy was employed in 22 of 53 patients (42%) with the most common agents being cyclophosphamide in 22 and doxorubicin in 11.
  • Five of 6 infants <6 months of age and 1 of 7 >/=6 months developed musculoskeletal toxicity.
  • Musculoskeletal effects were seen in 6 RT patients and included bony hypoplasia in 6, scoliosis in 5, soft tissue hypoplasia in 3, slipped capital femoral epiphysis in 2, kyphosis in 1, and osteochondroma in 1.
  • Three required orthopedic intervention, all receiving >/=20 Gy.
  • One child developed bowel obstruction at 21 months and another developed a leiomyosarcoma in the treatment field 34 years after RT.
  • Further studies are needed to determine if cardiovascular anomalies are more frequently seen in children with neuroblastoma.
  • [MeSH-major] Neuroblastoma / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Male. Musculoskeletal Diseases / etiology. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Radiation Injuries / complications. Survival Rate. Thoracic Neoplasms / mortality. Thoracic Neoplasms / pathology. Thoracic Neoplasms / radiotherapy. Treatment Failure

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1575; author reply 1575 [12459387.001]
  • (PMID = 11958898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Milam MR, Gabel SF, Milam RA, Liu J, Ramirez PT: Neoadjuvant bleomycin, etoposide, and cisplatin in adult neuroblastoma arising from the broad ligament of the uterus. Gynecol Oncol; 2007 Nov;107(2):350-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant bleomycin, etoposide, and cisplatin in adult neuroblastoma arising from the broad ligament of the uterus.
  • BACKGROUND: A case of primary neuroblastoma arising from the broad ligament with excellent response to neoadjuvant bleomycin, etoposide, and cisplatin (BEP) is reported.
  • CASE: A 48-year-old woman, G0, who presented with acute renal failure, an enlarged pelvic mass, and abdominal pain was diagnosed with adult neuroblastoma arising from the broad ligament of the uterus.
  • She received three cycles of neoadjuvant therapy consisting of bleomycin, etoposide, and cisplatin (BEP) given every 3 weeks and had an excellent initial response.
  • The patient died of recurrent disease 20 months after her initial diagnosis.
  • CONCLUSIONS: The clinical management of cancer in the broad ligament of the uterus must be tailored to the pathologic diagnosis.
  • Although our patient had an excellent initial response to BEP, further study is needed to identify a treatment that can reduce recurrences and improve clinical outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Broad Ligament. Neoadjuvant Therapy / methods. Neuroblastoma / drug therapy. Neuroblastoma / surgery. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881040.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • Stage was defined by the International Neuroblastoma Staging System.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • The absence of cortical bone and extensive bone marrow metastatic involvement in a young neuroblastoma patient should cause a shift in attention to biologic prognostic markers.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


21. Mata F, Losa F, Camacho L, Fernandez Trigo V, Barrios P, Mas J: Peripheral primitive neuroectodermal tumor (PPNET) of pelvic origin: report of a case arising from an unusual location. Tumori; 2001 Mar-Apr;87(2):109-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor (PPNET) of pelvic origin: report of a case arising from an unusual location.
  • Physical examination and CT scan revealed a pelvic mass occupying the entire pelvic cavity.
  • The diagnostic workup included a CT-guided biopsy which defined the tumor as a sarcomatous type.
  • Radical surgery was performed including tumor resection, pelvic exenteration (bladder and prostate gland) and urinary and fecal diversion.
  • Adjuvant chemotherapy (VAIA) was delivered once the histology was confirmed.
  • We reviewed the available literature focusing on the varied nomenclature of this tumor (peripheral neuroepithelioma, Askin's tumor, Ewing's extraosseous tumor, peripheral adult neuroblastoma, peripheral primitive extracranial neuroectodermal tumor (PPNET), the clinical features, the role of diagnostic imaging techniques, pathologic assessment and controversial therapeutic management.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Infant. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11401207.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wilkins S, Pilling D, Buxton N, Pizer B: Pelvic teratoma with extensive spinal involvement in a neonate: an important differential diagnosis. Br J Neurosurg; 2008 Jun;22(3):426-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic teratoma with extensive spinal involvement in a neonate: an important differential diagnosis.
  • Clinical and radiological features indicated a diagnosis of congenital neuroblastoma.
  • Histology revealed a diagnosis of germ cell tumour after therapy for neuroblastoma had been commenced.
  • [MeSH-major] Neuroblastoma / diagnosis. Pelvic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Spinal Cord Compression / etiology. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Female. Humans. Hypertension / drug therapy. Infant. Neoplasm, Residual / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568732.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JEB protocol
  •  go-up   go-down


23. Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C, Bernard JL, Stephan JL, Bouffet E, Buclon M, Combaret V, Fourquet A, Philip T, Zucker JM: LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol; 2000 Feb;18(3):468-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis.
  • PURPOSE: To tailor postinduction therapy for stage 4 neuroblastoma in children who are older than 1 year at diagnosis according to status after induction.
  • After induction with the French Society of Pediatric Oncology NB87 regimen and surgery, patients who were in complete remission immediately proceeded to consolidation therapy with vincristine, melphalan, and fractionated total-body irradiation (VMT).
  • All other patients underwent a postinduction strategy before VMT, either an additional megatherapy regimen or further chemotherapy with etoposide/carboplatin.
  • RESULTS: The progression-free survival (PFS) is 29% at 7 years from diagnosis, which compares favorably with that of a similar cohort of 72 patients previously reported by our group (LMCE1; PFS of 20% at 5 years and 8% at 14 years, P =.004).
  • In the multivariate analysis, only age younger than 3 years at diagnosis (P =.0085) and achievement of complete or very good partial remission after NB87 and surgery (P =.00024) remained significant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Multivariate Analysis. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Remission Induction. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653862.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Paliwal VK, Chandra S, Verma R, Kalita J, Misra UK: Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis? J Neural Transm (Vienna); 2010 May;117(5):613-5
Hazardous Substances Data Bank. CLONAZEPAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Opsoclonus myoclonus syndrome is a rare paraneoplastic syndrome seen in 50% of children with neuroblastoma.
  • [MeSH-major] Cerebellar Nuclei / drug effects. Cerebellar Nuclei / physiopathology. Clonazepam / administration & dosage. Neural Inhibition / drug effects. Opsoclonus-Myoclonus Syndrome / drug therapy. Opsoclonus-Myoclonus Syndrome / physiopathology
  • [MeSH-minor] Autoantibodies / metabolism. Cerebellar Cortex / immunology. Cerebellar Cortex / metabolism. Cerebellar Cortex / physiopathology. Efferent Pathways / immunology. Efferent Pathways / metabolism. Efferent Pathways / physiopathology. GABA Modulators / administration & dosage. Humans. Infant. Male. Neuroblastoma / complications. Neuroblastoma / immunology. Neuroblastoma / surgery. Neurosurgical Procedures. Pelvic Neoplasms / complications. Pelvic Neoplasms / immunology. Pelvic Neoplasms / surgery. Purkinje Cells / immunology. Purkinje Cells / metabolism. Purkinje Cells / pathology. Treatment Outcome. gamma-Aminobutyric Acid / metabolism

  • Genetic Alliance. consumer health - Dancing Eyes-Dancing Feet Syndrome.
  • Genetic Alliance. consumer health - Myoclonus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropharmacol. 1992 Jun;15(3):186-228 [1394242.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Exp Brain Res. 2005 Jan;160(1):89-106 [15289966.001]
  • [Cites] Pediatr Neurol. 1997 May;16(4):334-6 [9258970.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):313-7 [15988749.001]
  • [Cites] Neurology. 1968 Nov;18(11):1041-6 [5752588.001]
  • [Cites] Cancer. 1976 Feb;37(2):846-52 [1253109.001]
  • [Cites] Neurology. 2003 Aug 12;61(3):412-5 [12913213.001]
  • [Cites] Curr Opin Neurol. 2007 Feb;20(1):25-31 [17215685.001]
  • [Cites] Eur Neurol. 2006;56(4):240-2 [17057386.001]
  • [Cites] Indian J Ophthalmol. 1996 Jun;44(2):101-2 [8916599.001]
  • (PMID = 20094737.001).
  • [ISSN] 1435-1463
  • [Journal-full-title] Journal of neural transmission (Vienna, Austria : 1996)
  • [ISO-abbreviation] J Neural Transm (Vienna)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / GABA Modulators; 56-12-2 / gamma-Aminobutyric Acid; 5PE9FDE8GB / Clonazepam
  •  go-up   go-down


25. Parigi GB, Beluffi G, Corbella F, Matteotti C, Ramella B, Bragheri R: Long-term follow-up in children treated for retroperitoneal malignant tumours. Eur J Pediatr Surg; 2003 Aug;13(4):240-4
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up in children treated for retroperitoneal malignant tumours.
  • Thirty-two long-term survivors after treatment with surgery, radiotherapy and chemotherapy for neuroblastoma (NRB) and Wilms' tumour (WT) were re-evaluated after a period of more than 10 years (mean 16 yr 1 mo, range 27 yr 2 mo/10 yr 5 mo).
  • Spinal X-rays revealed mild kyphotic deformities (68.9 %), pelvic obliquity and tilting (62.5 %), rotation of the vertebral bodies (34.3 %) and compensatory curves of the spine (21.8 %).
  • In conclusion, the study emphasises the need for careful and prolonged follow-up for the detection of sequelae than can appear even many years after the initial treatment, and the wisdom and the need for a continued search for less aggressive protocols; as long as the cure rate is not compromised, less aggressive protocols should aim for a satisfactory overall survival with a reduced incidence of sequelae and hence a better quality of life.
  • [MeSH-major] Neuroblastoma / therapy. Retroperitoneal Neoplasms / therapy. Surgical Procedures, Operative / methods. Wilms Tumor / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Infant. Male. Nephrectomy / methods. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680492.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M: A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res; 2001 Jan;7(1):32-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An MTD was defined in heavily pretreated and less-heavily pretreated (i.e., two prior chemotherapy regimens, no prior bone marrow transplantation, and no radiation to the spine, skull, ribs, or pelvic bones) patients.
  • A partial response was observed in one patient with neuroblastoma, and in one patient with hepatocellular carcinoma.
  • Stable disease (4-20 cycles) was observed in seven patients with a variety of malignancies including neuroblastoma, pineoblastoma, glioblastoma, brainstem glioma, osteosarcoma, hepatoblastoma, and a central nervous system rhabdoid tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Enzyme Inhibitors / therapeutic use. Neoplasms / drug therapy. Topoisomerase I Inhibitors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematologic Tests. Humans. Infant. Infusions, Intravenous. Male. Toxicity Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205914.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / MO1RR00188; United States / NCI NIH HHS / CA / U01CA57745
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement